Pentosan Polysulfate (PPS)

PPS is a low-molecular-weight heparin-like compound with structural similarity to endogenous glycosaminoglycans. In the bladder, it is proposed to adhere to and replenish the GAG layer on the urothelial surface, which serves as a barrier protecting the underlying bladder wall from urinary irritants (potassium, urea, toxins). By restoring this barrier, PPS may reduce the sensory nerve activation and mast cell degranulation that drive IC symptoms. PPS also has weak anticoagulant activity (approximately 1/15 the potency of heparin), anti-inflammatory properties, and has demonstrated inhibition of complement activation and histamine release. In cartilage models, PPS stimulates proteoglycan and hyaluronic acid synthesis by chondrocytes and inhibits matrix metalloproteinases involved in cartilage degradation.

Parsons et al. (1987) conducted the pivotal placebo-controlled trial demonstrating PPS efficacy for IC, with symptom improvement in approximately 28% of PPS patients vs 13% on placebo. Multiple subsequent trials confirmed modest efficacy, and PPS received FDA approval for IC in 1996. Response rates across studies have generally been modest (30 to 50%), and symptom improvement typically requires 3 to 6 months of continuous use. For osteoarthritis, evidence is primarily from veterinary studies and small pilot human trials. The off-label OA use is not supported by large RCTs. Pearce et al. (2018) identified a novel pigmentary maculopathy in long-term PPS users, a finding that was subsequently confirmed in larger observational studies and led to FDA label revision in 2020.

PPS (Elmiron) received FDA approval in 1996 for relief of bladder pain or discomfort associated with interstitial cystitis. It is manufactured by Janssen Pharmaceuticals. The label was updated in 2020 to include warnings about pigmentary maculopathy. No FDA-approved indication exists for osteoarthritis; that use is strictly off-label. PPS is available by prescription only in the United States.

Baseline ophthalmologic examination recommended before starting PPS, with periodic follow-up (annually or as clinically indicated) for patients on long-term therapy. Ophthalmologic screening should include visual acuity, OCT, and fundus autofluorescence. Monitor for signs of bleeding, especially in patients on concurrent anticoagulant or antiplatelet therapy. Hepatic function tests at baseline. Patient symptom assessment at 3 to 6 months to evaluate therapeutic response before committing to long-term use.

These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.

Elmiron (PPS 100 mg capsules) should be stored at controlled room temperature (20 to 25 degrees C). Protect from moisture. No special reconstitution is required as it is an oral capsule formulation. Expiration dating follows manufacturer specifications on the product label.

1. 1

   FDA label

   ELMIRON (pentosan polysulfate sodium) Prescribing Information

   Janssen Pharmaceuticals (2020). FDA

   Key findings: FDA-approved for relief of bladder pain or discomfort associated with interstitial cystitis. Updated labeling includes warnings about pigmentary maculopathy with long-term use.

   Limitations: Label information; not primary research.

   View source
2. 2

   RCT

   A Randomized, Double-Blind, Placebo-Controlled Trial of Pentosan Polysulfate Sodium for Interstitial Cystitis

   Parsons CL, Mulholland SG. (1987). Journal of Urology

   Key findings: PPS demonstrated statistically significant improvement in bladder pain, urgency, and frequency compared to placebo in patients with interstitial cystitis. Response rates were approximately 28% for PPS vs 13% for placebo.

   Limitations: Modest effect sizes. Older trial with less rigorous methodology by current standards.

3. 3

   observational

   Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium

   Pearce WA, Chen R, Jain N. (2018). Ophthalmology

   Key findings: Identified a novel pigmentary maculopathy in 6 patients with long-term PPS use (average 15 years). Pattern of pigment deposits on fundoscopy and characteristic findings on OCT and fundus autofluorescence. May be irreversible.

   Limitations: Case series (n=6). Retrospective. Causality not definitively established but led to FDA label update.

   View source